Nov 1, 2002
By:
Joanna Breitstein
The year 2003 will bring more than glad tidings for the New England Journal of Medicine. Jeffrey M. Drazen, MD, editor-in-chief, unveiled the peer-reviewed journal's new design at a recent luncheon hosted for pharma executives, media planners, and agency representatives.
|
Nov 1, 2002
By:
Joanna Breitstein
In early October, the Advertising Club of New York sponsored a luncheon titled "Rx for Drug Marketers: Tackling DTC."
|
Nov 1, 2002
By:
Joanna Breitstein
Michael Sullivan, senior director of marketing communications for Incyte Genomics, discusses the challenges of communicating company changes to stakeholders.
|
Oct 1, 2002
By:
Joanna Breitstein
FDA may approve new medications that treat alcohol, nicotine, cocaine, and heroin addictions, but marketers must overcome the many challenges associated with selling them.
|
Oct 1, 2002
By:
Joanna Breitstein
Although the stream of venture capital dollars decreased for most industries from the first to second quarter of 2002, Growthink Research reports that investments in healthcare companies increased.
|
|
Oct 1, 2002
By:
Joanna Breitstein
FDA will launch a one-year advertising campaign that aims to build patients' confidence in generic medications. The effort includes brochures, radio and print public service announcements, a website, and a MAT release, a written story in a ready-to-use format that is distributed to small local and low-tier publications. Television advertising won't be a part of the campaign.
|
Oct 1, 2002
By:
Joanna Breitstein
CNN's new policy of full disclosure of celeb-rities' financial ties with pharma companies drew media attention from the New York Times and other outlets. Megan Mahoney, who works in CNN's public relations department, said that, in light of recent attention surrounding paid celebrity endorsements, the company became aware that some celebrities discussing health problems might be paid and changed its policy.
|
Oct 1, 2002
By:
Joanna Breitstein
Schering-Plough's Clarinex (desloratadine) sampling efforts have been an effective vehicle for getting the new product into physicians' medicine cabinets.
|
Sep 1, 2002
By:
Joanna Breitstein
Physicians and the medical societies they belong to lag behind patients in building effective online communities. Although industry observers dismiss doctors as "late adopters" of new technology, the truth is that healthcare professionals will collaborate over the web only when they deem it beneficial-when it saves time or money or improves the quality of patient care.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
